Despite decades of advances in its prevention and the development of treatment, cardiovascular disease remains the world’s #1 killer.1 But how do you motivate people to join and comply with your lengthy studies – people who have frequently succumbed to such a state because they have not been motivated or educated enough to do anything about it? Well, if you let us help you, patient recruitment is just one of the things you won’t have to worry about.
Capture high-quality data safely and with global consistency
Our web-based electronic endpoint adjudication system is especially tailored for long-term, large-scale, global cardiovascular studies. We’ll use it together with our innovative data monitoring strategies. They employ risk-based techniques encouraged by regulatory authorities to improve patient safety at the same time as providing cost efficiencies.
We collaborate with the people you need us to
Over the decades spent working in this area, we’ve developed close working ties with academic research organizations and experienced investigators who supplement our experience and passion in getting your cardiovascular medicines to the people who need them.
Our close contact with regulatory agencies means we give your studies a clear path to regulatory approval and ensure we’re always working in a way that’s acceptable to them.
Take a look at our experience
We’ve conducted studies and given advice covering CV endpoints (MACE), pharmacologic, biologic and stem cell interventions for a wide range of indications, including:
- Acute coronary syndrome
- Angina pectoris
- Cardiothoracic surgery
- Deep vein thrombosis
- Heart failure
- Ischemic heart disease
- Peripheral arterial disease
- Pulmonary Hypertension
- Renal failure (acute and chronic)
- Venous thromboembolism (VTE)
We can help you get the medicines to the people who need them, sooner.
a This is an estimate of INC Research studies from the last five years that are completed or scheduled to complete for this therapy area.